Blog
RSS FeedPosted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 26 Sep 2018
Quality assurance of registries for health technology assessment
25 September 2018 - The aim of this study was to identify guidelines and assessment tools used by health technology agencies ...
Posted by Michael Wonder on 06 Aug 2018
Division on European HTA
3 August 2018 - There have been aspirations for closer collaboration between European Union Member States on health technology assessment for ...
Posted by Michael Wonder on 13 Jul 2018
Getting it right: EPHA recommendations on how to improve the European Commission proposal on health technology assessment
11 July 2018 - The European Public Health Alliance welcomes the European Commission proposal for a regulation on health technology ...
Posted by Michael Wonder on 24 Jun 2018
Industry urges EU to scrap national HTA bodies
22 June 2018 - The pharma industry has called for European member states’ national drug value assessment bodies to be ...
Posted by Michael Wonder on 19 Jun 2018
Patients call for end to two-year row over cystic fibrosis drug funding
19 June 2018 - UK patients are stepping up efforts to resolve the “heartbreaking” row that is denying their families ...
Posted by Michael Wonder on 12 Jun 2018
Who should pay for HTA?
11 June 2018 - Part of the drive for strengthening EU cooperation on health technology assessment is to tackle duplication ...
Posted by Michael Wonder on 07 Jun 2018
UK health spends lags behind EU peers
7 June 2018 - The amount the UK spends on health falls well behind that invested by European peers such ...
Posted by Michael Wonder on 02 Jun 2018
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
31 May 2018 - Innovative pricing agreements for medicines have been used in European markets for more than 20 years, ...
Posted by Michael Wonder on 16 May 2018
Patient empowerment in Europe: is no further research needed?
15 May 2018 - In economic theory, health care can be considered a clear example of ‘market failure’ caused by ...
Posted by Michael Wonder on 10 May 2018
EFPIA welcomes HTA proposals from Commission
10 May 2018 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the European Commission’s proposal for ...
Posted by Michael Wonder on 09 May 2018
Rare diseases: addressing the challenges in diagnosis, drug approval, and patient access
9 May 2018 - Rare diseases represent a wide range of disorders and constellations of clinical signs and symptoms. ...
Posted by Michael Wonder on 22 Mar 2018
Harmonised health technology assessment in Europe? There’s a long way to go
22 March 2018 - Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices ...
Posted by Michael Wonder on 19 Mar 2018
Funding breakthrough therapies: a systematic review and recommendation
17 March 2018 - Advanced therapy medicinal products are innovative therapies likely associated with high prices. ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...